Learn / Clinical Research Management / Safety in clinical trials
Safety reporting timelines and oversight committees
12 minute read · 6-question quiz
What you will learn
Describe expedited reporting of SUSARs and annual safety reports
Explain the role of a data safety monitoring board
Describe what happens when a safety signal emerges
Safety reporting involves several parties, each with duties and deadlines.
Who reports what, and when
- Investigator to sponsor: all SAEs immediately, typically within 24 hours of awareness, with a full follow-up report.
- Sponsor to regulators and ethics committees: SUSARs are reported on an expedited basis. In ICH-based systems the usual standard is 7 calendar days for fatal or life-threatening SUSARs (with follow-up information within a further 8 days) and 15 calendar days for other SUSARs. Local rules differ, so always check the requirements of each regulator and ethics committee.
- Sponsor to investigators: safety information that affects the study, including updated investigator brochures and urgent safety measures.
- Periodic reports: an annual safety report (such as the Development Safety Update Report, DSUR) summarises safety data across the programme, and ethics committees receive annual progress reports.
- Urgent safety measures: immediate action to protect participants from a hazard may be taken before approval and then notified.
Data safety monitoring boards
A data and safety monitoring board (DSMB, or DMC) is an independent group of experts, often including clinicians, a statistician and an ethicist, that reviews accumulating unblinded data to protect participants and the trial's integrity.
- It reviews safety, and sometimes efficacy, at pre-planned intervals.
- It can recommend that the trial continue unchanged, be modified, be paused or be stopped for harm, clear benefit or futility.
- Its recommendations go to the sponsor, which makes the final decision.
- Members must be independent of the sponsor and investigators.
- Its work is governed by a charter that sets out membership, meeting schedule, confidentiality and decision rules.
Safety signals and stopping rules
A safety signal is information suggesting a new or changed risk. The sponsor and DSMB assess signals using cumulative data, comparing event rates between arms. Protocols often define stopping or pausing rules, such as pausing enrolment if two participants have the same severe reaction in a short period.
Summary
Investigators report SAEs to the sponsor within about 24 hours; sponsors report SUSARs to regulators and ethics committees on expedited timelines.
Fatal or life-threatening SUSARs usually 7 days (plus follow-up), others 15 days under ICH-based systems.
A DSMB independently reviews unblinded data and advises continuing, modifying, pausing or stopping.
Protocols define stopping and pausing rules for safety signals.
Check your understanding
Draft study guide. Spotted an error or something unclear? Tell us at hello@scintria.com. This is educational material, not clinical or regulatory advice.